Search Results - "Jäderberg, Magnus"

Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma by Shoushtari, Alexander N, Olszanski, Anthony J, Nyakas, Marta, Hornyak, Thomas J, Wolchok, Jedd D, Levitsky, Victor, Kuryk, Lukasz, Hansen, Thomas B, Jäderberg, Magnus

“…Intratumoral oncolytic virotherapy may overcome anti-PD(L)-1 resistance by triggering pro-inflammatory remodeling of the tumor microenvironment. This pilot…”
Get full text

Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model by Kuryk, Lukasz, Møller, Anne-Sophie W., Jaderberg, Magnus

“…Malignant melanoma is an aggressive type of skin cancer whose incidence is increasing globally. Although surgery is effective in early stage melanoma, patients…”
Get full text

Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks by Kuryk, Lukasz, Møller, Anne-Sophie W, Vuolanto, Antti, Pesonen, Sari, Garofalo, Mariangela, Cerullo, Vincenzo, Jaderberg, Magnus

“…Oncolytic adenoviruses can trigger lysis of tumor cells, induce an antitumor immune response, bypass classical chemotherapeutic resistance strategies of…”
Get full text

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment by Ponce, Santiago, Cedrés, Susana, Ricordel, Charles, Isambert, Nicolas, Viteri, Santiago, Herrera-Juarez, Mercedes, Martinez-Marti, Alex, Navarro, Alejandro, Lederlin, Mathieu, Serres, Xavier, Zugazagoitia, Jon, Vetrhus, Sylvia, Jaderberg, Magnus, Hansen, Thomas Birkballe, Levitsky, Victor, Paz-Ares, Luis

“…Background ONCOS-102, an oncolytic adenovirus expressing granulocyte-macrophage colony-stimulating factor, can alter the tumor microenvironment to an…”
Get full text

368 Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors by Kuryk, Lukasz, Moller, Anne-Sophie, Kumar, Sandeep, Shoushtari, Alexander, Ares, Luis Paz, Jaderberg, Magnus, Wiklund, Erik Digman, Levitsky, Victor

“…BackgroundSolid tumors exhibit highly variable compositions of immune infiltrates. Therapeutic compounds driving uniform remodeling of tumor microenvironment…”
Get full text

Pilot study of ONCOS-102 and pembrolizumab: remodeling of the tumor micro-environment and clinical outcomes in anti-PD1-resistant advanced melanoma by Shoushtari, Alexander, Olszanski, Anthony J., Nyakas, Marta, Hornyak, Thomas J., Wolchok, Jedd D., Levitsky, Victor, Kuryk, Lukasz, Hansen, Thomas B., Jäderberg, Magnus

Get full text

462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data by Jaderberg, Magnus, Paz-Ares, Luis, Cedres, Susana, Ricordel, Charles, Isambert, Nicolas, Aix, Santiago Ponce, Levitsky, Victor, Kuryk, Lukasz, Moller, Anne-Sophie, Vetrhus, Sylvia

“…BackgroundMalignant pleural mesothelioma (MPM) is an aggressive malignancy without curative treatment. Standard of care (SOC) include pemetrexed/cisplatin and…”
Get full text

361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes by Jaderberg, Magnus, Cedres, Susana, Paz-Ares, Luis, Serres, Xavier, Ricordel, Charles, Isambert, Nicolas, Aix, Santiago Ponce, Levitsky, Victor, Kuryk, Lukasz, Moller, Anne-Sophie, Vetrhus, Sylvia

“…BackgroundMalignant pleural mesothelioma (MPM) is a rare, aggressive malignancy without curative treatment. Majority of patients receive pemetrexed/cisplatin…”
Get full text

Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma by Kuryk, Lukasz, Møller, Anne‐Sophie W., Jaderberg, Magnus

“…Melanoma, an immunogenic tumor, is the first indication where oncolytic viruses are now becoming part of clinical practice. ONCOS‐102, a transgened adenovirus,…”
Get full text

Final survival outcomes and immune biomarker analysis of a randomized, open-label, phase I/II study combining oncolytic adenovirus ONCOS-102 with pemetrexed/cisplatin (P/C) in patients with unresectable malignant pleural mesothelioma (MPM) by Ponce, Santiago, Cedres Perez, Susana, Ricordel, Charles, Isambert, Nicolas, Levitsky, Victor, Hansen, Thomas Birkballe, Jaderberg, Magnus Erik, Paz-Ares, Luis G.

“…8561 Background: MPM is an aggressive malignancy without curative treatment. ONCOS-102 is an oncolytic adenovirus expressing GM-CSF (Ad5/3-D24-GMCSF) with a…”
Get full text

Local immunotherapy with ONCOS-102 shapes harmful tumor associated CD68+ macrophages to become beneficial cells that correlate with increased overall survival by Pesonen, Sari, Lundin, Johan, Linder, Nina, Turkki, Riku, Ristimäki, Ari, Joensuu, Timo, Kairemo, Kalevi, Partanen, Kaarina, Alanko, Tuomo, Jäger, Elke, Karbach, Julia, Wahle, Claudia, Hemminki, Akseli, Backman, Charlotta, von Euler, Mikael, Hakonen, Tiina, Ranki, Tuuli, Vuolanto, Antti, Jäderberg, Magnus, Zamarin, Dmitry

Get full text

Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401 by Kuryk, Lukasz, Møller, Anne-Sophie W., Jaderberg, Magnus

“…Adaptive immunity involves activation of T cells via antigen presentation by antigen presenting cells (APCs) along with the action of co-stimulatory molecules…”
Get full text

Antitumor‐specific T‐cell responses induced by oncolytic adenovirus ONCOS‐102 (AdV5/3‐D24‐GM‐CSF) in peritoneal mesothelioma mouse model by Kuryk, Lukasz, Møller, Anne‐Sophie W., Garofalo, Mariangela, Cerullo, Vincenzo, Pesonen, Sari, Alemany, Ramon, Jaderberg, Magnus

“…Oncolytic adenoviral immunotherapy activates the innate immune system with subsequent induction of adaptive tumor‐specific immune responses to fight cancer…”
Get full text

Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers by Ranki, Tuuli, Pesonen, Sari, Hemminki, Akseli, Partanen, Kaarina, Kairemo, Kalevi, Alanko, Tuomo, Lundin, Johan, Linder, Nina, Turkki, Riku, Ristimäki, Ari, Jäger, Elke, Karbach, Julia, Wahle, Claudia, Kankainen, Matti, Backman, Charlotta, von Euler, Mikael, Haavisto, Elina, Hakonen, Tiina, Heiskanen, Raita, Jaderberg, Magnus, Juhila, Juuso, Priha, Petri, Suoranta, Laura, Vassilev, Lotta, Vuolanto, Antti, Joensuu, Timo

“…We conducted a phase I study with a granulocyte macrophage colony stimulating factor (GMCSF)-expressing oncolytic adenovirus, ONCOS-102, in patients with solid…”
Get full text

Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results by Zamarin, Dmitriy, Odunsi, Kunle, Zsiros, Emese, Slomovitz, Brian M., Pimentel, Agustin, Duska, Linda R., Reilley, Matthew, Nemunaitis, John J., Hamouda, Danae M., Patel, Hitendra, Segal, Neil Howard, Pesci, Giulio, Holland, Aliya, Shohara, Lisa, Schwarzenberger, Paul Otto, Ricciardi, Toni, Macri, Mary J., Ryan, Aileen, Jaderberg, Magnus Erik, Venhaus, Ralph Rudolph

“…2600 Background: Locoregional treatment with oncolytic viruses may be used to improve the efficacy of immune checkpoint inhibitors at both treated and distant…”
Get full text

Phase I/II study to evaluate systemic durvalumab + intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase I clinical and translational results by Zamarin, Dmitriy, Odunsi, Kunle, Slomovitz, Brian M., Duska, Linda R., Nemunaitis, John J., Reilley, Matthew, Bykov, Yonina, Holland, Aliya, Hubbard-Lucey, Vanessa M., Shohara, Lisa, Schwarzenberger, Paul, Ricciardi, Toni, Macri, Mary J., Ryan, Aileen, Jaderberg, Magnus Erik, Venhaus, Ralph Rudolph

“…Abstract only 3017 Background: Metastasis to the peritoneal cavity is associated with end-stage disease in many cancers, including OC and CRC, both of which…”
Get full text

Abstract 1983: Modulation of immune gene expression by intra-tumoral oncolytic adenovirus ONCOS-102 is associated with clinical response in anti-PD-1 refractory/resistant melanoma by Wiklund, Erik Digman, Kuryk, Lukasz, Kumar, Sandeep, Jaderberg, Magnus, levitsky, Victor, Hansen, Thomas Birkballe, Moller, Anne-Sophie, Shoushtari, Alexander

“…Abstract Background: Defining molecular parameters of clinical response to immune modulators may lead to development of novel biomarkers, new therapeutic…”
Get full text

Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8 + T-cell response, prominent infiltration of CD8 + lymphocytes and Th1 type polarization by Ranki, Tuuli, Joensuu, Timo, Jäger, Elke, Karbach, Julia, Wahle, Claudia, Kairemo, Kalevi, Alanko, Tuomo, Partanen, Kaarina, Turkki, Riku, Linder, Nina, Lundin, Johan, Ristimäki, Ari, Kankainen, Matti, Hemminki, Akseli, Backman, Charlotta, Dienel, Kasper, von Euler, Mikael, Haavisto, Elina, Hakonen, Tiina, Juhila, Juuso, Jaderberg, Magnus, Priha, Petri, Vassilev, Lotta, Vuolanto, Antti, Pesonen, Sari

“…Late stage cancer is often associated with reduced immune recognition and a highly immunosuppressive tumor microenvironment. The presence of tumor infiltrating…”
Get full text

An evaluation of local and systemic immune markers following intratumoral administration of a chimeric adenovirus Ad5/3-D24-GMCSF in refractory cancer patients with solid tumors by Pesonen, Sari Anneli, Ranki, Tuuli, Jäger, Elke, Karbach, Julia, Wahle, Claudia, Joensuu, Timo K., Alanko, Tuomo, Partanen, Kaarina, Kairemo, Kalevi, Turkki, Riku, Linder, Nina, Lundin, Johan, Ristimäki, Ari, Majumder, Mamun, Kumar, Ashwini, Heckman, Caroline, Kankainen, Matti, Hemminki, Akseli, Von Euler, Mikael, Jaderberg, Magnus Erik

“…Abstract only…”
Get full text

Gene expression analysis of tumors demonstrates an induction of Th1 type immune response following intratumoral administration of ONCOS-102 in refractory solid tumor patients by Majumder, Mamun, Kumar, Ashwini, Heckman, Caroline, Kankainen, Matti, Pesonen, Sari, Jäger, Elke, Karbach, Julia, Joensuu, Timo, Kairemo, Kalevi, Partanen, Kaarina, Alanko, Tuomo, Hemminki, Akseli, Backman, Charlotta, Dienel, Kasper, von Euler, Mikael, Hakonen, Tiina, Juhila, Juuso, Ranki, Tuuli, Vassilev, Lotta, Vuolanto, Antti, Jaderberg, Magnus

“…Advanced tumors are often immunosuppressive. Intratumoral administration of adenovirus activates Toll-like receptor signalling leading to production of…”
Get full text